Research programme: antifungals - Ceragenix

Drug Profile

Research programme: antifungals - Ceragenix

Alternative Names: CGX-813

Latest Information Update: 07 May 2010

Price : $50

At a glance

  • Originator Ceragenix Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Mycoses

Most Recent Events

  • 07 May 2010 Discontinued for Mycoses in USA (Topical)
  • 22 May 2008 Early research in Mycoses in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top